Cranbury Pharmaceuticals has begun shipping the first US generic version of PTC Therapeutics’ Emflaza (deflazacort) oral suspension for the treatment of Duchenne muscular dystrophy, after the brand’s seven-year period of orphan drug exclusivity for treatment of DMD in patients five years and older expired in February this year.
The New Jersey-based company is a new subsidiary of Tris Pharma, which has handed over its generics portfolio and pipeline...